Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference
Palvella Therapeutics (Nasdaq: PVLA) announced that Founder and CEO Wes Kaupinen will present at the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025 at 4:00 p.m. ET.
Rhea-AI Summary
Palvella Therapeutics (Nasdaq: PVLA) announced that Founder and CEO Wes Kaupinen will present at the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025 at 4:00 p.m. ET.
A live webcast will be available on the company's Events and Presentations page at www.palvellatx.com, and an archived replay will be accessible for approximately 90 days after the presentation.
Details
News Market Reaction – PVLA
On Nov 6, the day this news came out, PVLA closed 3.80% above the previous close.
Data tracked by StockTitan Argus for the Nov 6 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will present at the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025, at 4:00 p.m. ET.
A live webcast of the presentation will be available on the Events and Presentations section of Palvella's website at www.palvellatx.com. An archived replay of the webcast will be available for approximately 90 days following the presentation.
About Palvella Therapeutics
Founded and led by rare disease drug development veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare skin diseases, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN™
QTORIN™ rapamycin and QTORIN™ pitavastatin are for investigational use only and neither has been approved or cleared by the FDA or by any other regulatory agency for any indication.
Contact Information
Investors
Wesley H. Kaupinen
Founder and CEO, Palvella Therapeutics
wes.kaupinen@palvellatx.com
Media
Marcy Nanus
Managing Partner, Trilon Advisors LLC
mnanus@trilonadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.